Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Violin - re. your 10.39 - you can send a PM on ADVFN. It'd be good to have that pint.
Hi TakeStock - Puritas eh? Those were the days! I wish we could look back on all the posts from that time but they were wiped long ago. Do you remember other names from that era?
Regarding 'potential valuations' - $10 billion for 4 platforms, remains feasible, if all goes well, (that's a comment on 'potential', not a forecast), and you're not alone being in deficit btw, my average is 17p as I haven't traded at all.
Time will tell! Indeed - the question is, how much time before it tells! ATB
Thanks for that Johnny - I remembered a mention of JPM before, but if NINE years ago it was, it goes to show I've been around here far too long !!
That RNS states that RG/LD as joint CEO's were giving an update 'coincident with' the JPM Conference, but in San Francisco, which might imply, they were not actually at JPM but making an address elsewhere, maybe at a 'fringe' venue. I can't see any prior announcement of Scancell having been invited to attend JPM, which would have been the normal way of things.
On that occasion 'corporate presentations' were being made, in fact a SCIB1 Phase1/2 update, maybe the same data mentioned in the half yearly report the month before., Dec 2014. RG and LD traveled, (khas joint CEO's).
I worked back from P.7 through the lists of RNS but I couldn't see that Scancell had ever actually attended the JPM before - but I stand to be corrected.
So Sath is blazing a trail tomorrow - reading between the lines, I'd guess he's been invited for some 'meets' and will be networking in his circles, like crazy. Good luck to him. An RNS would be good - it's intriguing!
All good fun . . . .
Violin - your 50p target. I have a small amount at 12p that I bought aeons ago from say, a 'current' rather than a 'capital' account and I'd unload that quantity if the SP approached 50p. However, I'll be hanging on for a lot more than 50p from my main holding, because, that potential IS there.
Up to you of course, but if the good news starts piling in, don't sell out too cheaply - I'm just suggesting. Talk of 50p as a target I find vaguely defeatist, (even though, it would be great right now LOL). ATB
Violin - re your 14.59 on the 6th. Speculating and hoping are different? Speculating IMO is based on a fact or some facts and hoping is well, hoping. A fact we found out belatedly, is that Sath is at JPM - fair to speculate on that, or be intrigued at least.
I'm just against building 'castles in the sky', because it switches to disappointment regularly - but, the science will see us through!
BTW I agree with Balerno that this will be, at last, the pivotal year for Scancell.
Dalester I'd be surprised if CFO can alone, sign or 'deal' on anything. But you never know . . .
" I assume a US listing might be on the agenda" - yes it might or might not be - exploratory discussions perhaps? Assessing options?
I agree with your optimistic view. Whilst I don't think we should give this JPM too much build up, CFO attending as a Visitor is both curious and intriguing.
WTP 10.08 I agree - but "attendance"? It's just we have a Guy there . . .
Violin - all good exposure? But it's not a Poster or an Address.
Cleaner 10.52 - I don't think, with respect, that a degree in Pharmacology will go far in science discussions in this gathering.
RW - I agree.
WTP 11.40 - "they feel they do not need to use it for a scientific platform". There's an assumption - I think maybe they're busy on much else - or weren't invited.
Violin - yes it's really good Sath is attending but IMO it would be because he has known 'meets' to do. In that way, Sath's attendance is intriguing.
Cleaner - agreed - "No one can afford to wait".
And GLA.
Hi Cleaner, re. 08.44, all very well but IMO your 15 indicators don't really point specifically to a JPM attendance at all. Myself I hadn't expected Scancell to attend JPM after attending a succession of Events lately and indeed, in terms of a Poster or an Address, we are not and it seems there's no one from the Science team going at all, at least AFAWK.
However, finding out that Sath is going, is still very interesting. I doubt that there'll be a resultant RNS on Monday but as he's not going to wander around doing nothing, I'm guessing he's there for some discussions with Invus, Pentwater, or Platinum and the like, indeed, some meets may already be arranged.
So all good stuff! Nice weekend to you.
Thanks Ciaskin/Dalester. Cleaner, very pleased to say I WAS wrong - it's good that we were 'told', even if not by RNS!
So no presentation or poster or science bods going but the CFO is - more than intriguing what he might be up to? Balerno thanks for yours. Sath has been invited, maybe arranged by Invus, Pentwater, or Platinum.
Fascinating news to wake up to.
Thanks Bobbust - yes Bazzoka noted that yesterday - good that Stifel are back!
I wonder why they left? Oh and 30p would do nicely right now. ATB
Hi Balerno - yes the statement is bullish for sure and maybe it was simply 'hardball' posturing in discussions that were intended to be private - Scancell are usually tight-lipped on this front. Encouragingly, a much higher SP would be envisaged needed to enable such a posture. AIMO
C11 I agree 100% with your 11.20 . . . . . 100% !
IMO there's been over-reaction to this 'tit bit' . . . .
Violin/Cleaner - catching up, it occurs to me that Lgbco have been very indiscreet in mentioning such a sensitive matter which, assuming it WAS said at all, would have been said in confidence with the CEO flying the flag in a scenario about which we just don't know anything at all.
However, IMO we should be reassured by these words also quoted, about such a move being made, "on the back of what they anticipate will be positive trial results".
The science will see us through . . . .
Hi C11 - I guess you refer to mine about the emerging JPM excitement, which is IMHO, probably misplaced. That's all.
As I said, I'd love to be wrong !! ATB
MattRempitt and Mayo - thank you for putting that into context. I'd forgotten the CEO's comment but anyway, I accept the cautionary words. Do you know what % payment we might get at any 'stage' along each of 3 paths, (assuming that there are 'stages' in fact)?
However, given that GenMab are a massive Company with effectively limitless resources, I find it hard to comprehend that it'll take them 5 years to move this science forward substantially - so let's hope anyway for something useful before that.
Thanks for posting.
Bazooka thanks and Burble re. ''Lindy noted that they will need a new contract manufacturer for iSCIB1" - any idea why that is? Is it ability to manufacture or window for manufacture? Thanks.
Burble, thanks for 12.19.
If/when the first milestone payment is received, it'll be more than 'interesting'. IMO, for Scancell to be seen moving along the path to $208 million x 1, 2 or 3 would arguably be transformational.
Am I right in thinking that on the path to, 'products developed and commercialised', we would be getting payments at stages along each of 3 paths?
TTBOMK the size these stage payments has not been specified as yet.
Yet another tantalising prospect in the Scancell armoury ! GLA
Me again Cleaner. Re. your 08.09 - indeed, as a massive established super-rich Company with 'well farmed' media connections, there is invariably an "abundance" of "media coverage" for anything Moderna.
I'm not sure if you are implying that therefore Scancell will receive a similar bounty when we have more news from the SCOPE trial. Somehow, I doubt that it will be that easy. However, more importantly, some movers and shakers around the Pharma, will at that stage know more about what's going on with Scancell.
The difficulties surrounding Moderna's 'personalised' approach have been described here with forensic clarity, to the point that convinced me, that, if SCOPE proves the 'Immunobody' effect, Moderna's ideas should surely, be booted right into touch because of the sheer impracticalities involved.
We'll see. ATB
Cleaner - re. your 14.50, I think it is safe to conclude that Scancell are NOT going to the JPM event and I think I'm right in saying, that we are usually told well in advance by RNS.
With SCOPE and MODI, it's a wait for more data, although Scancell have said there are "discussions ongoing with several Pharmaceutical and Biotech companies", on GlyMab and AvidiMab at least.
IF Scancell were attending the most we could hope for would be some helpful and progressive networking and IMO the idea that Conferences bring announcements of news/deals is misplaced. News is news and comes via RNS irrespective of the timing of Industry beanos . . . .
JPM is a major event but it's not relevant to Scancell's fortune or prospects - I would however, love to be wrong. ATB
Yep Violin - that's a little ! News to come . . . . . . ?